Page last updated: 2024-09-03

gefitinib and dalteparin

gefitinib has been researched along with dalteparin in 1 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(dalteparin)
Trials
(dalteparin)
Recent Studies (post-2010) (dalteparin)
5,2315662,9195,6651,4232,267

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L1

Other Studies

1 other study(ies) available for gefitinib and dalteparin

ArticleYear
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
    Molecular pharmacology, 2015, Volume: 87, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enoxaparin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rac GTP-Binding Proteins; Vimentin; Xenograft Model Antitumor Assays

2015